We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$725M
Cap. Flow %
-39.12%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 6.29%
2 Materials 0.25%
3 Financials 0.16%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
251
PUT
Ardelyx
ARDX
$1.24B
$40K ﹤0.01%
+160
New +$2.11K
BNTCW
252
DELISTED
Benitec Biopharma Limited
BNTCW
$37K ﹤0.01%
125,163
+27,017
+28% +$9.35K
GNMX
253
DELISTED
Aevi Genomic Medicine Inc
GNMX
$37K ﹤0.01%
19,888
-118,307
-86% -$535K
SYBX
254
DELISTED
Synlogic
SYBX
$24K ﹤0.01%
105
-849
-89% -$193K
CRIS icon
255
PUT
Curis
CRIS
$9.71M
– –
0
– –
HES
256
CALL
DELISTED
Hess
HES
$2K ﹤0.01%
250
-652
-72% -$34.5K
ACAD icon
257
CALL
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-6,470
Closed -$18.7M
ACAD icon
258
PUT
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-548
Closed -$1.58M
AGEN
259
PUT
Agenus
AGEN
$276M
– –
-128
Closed -$1.03M
AGIO icon
260
CALL
Agios Pharmaceuticals
AGIO
$2.08B
– –
-545
Closed -$2.27M
AKTX
261
Akari Therapeutics
AKTX
$14.4M
– –
-22
Closed -$120K
ALNY icon
262
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-13,823
Closed -$639K
AMRN
263
PUT
Amarin Corp
AMRN
$297M
– –
-56
Closed -$344K
ARCT icon
264
CALL
Arcturus Therapeutics
ARCT
$165M
– –
-443
Closed -$651K
ARCT icon
265
Arcturus Therapeutics
ARCT
$165M
– –
-13,123
Closed -$193K
ARCT icon
266
PUT
Arcturus Therapeutics
ARCT
$165M
– –
-80
Closed -$117K
ASRT
267
CALL
DELISTED
Assertio
ASRT
– –
-3
Closed -$335K
ATNM icon
268
Actinium Pharmaceuticals
ATNM
$26.3M
– –
-28,954
Closed -$760K
BIIB icon
269
CALL
Biogen
BIIB
$30.9B
– –
-115
Closed -$3.26M
BIIB icon
270
Biogen
BIIB
$30.9B
– –
-20,000
Closed -$5.67M
BIIB icon
271
PUT
Biogen
BIIB
$30.9B
– –
-100
Closed -$2.84M
BNTC icon
272
Benitec Biopharma
BNTC
$414M
– –
-998
Closed -$389K
BPMC
273
PUT
DELISTED
Blueprint Medicines
BPMC
– –
-190
Closed -$533K
CLRB icon
274
Cellectar Biosciences
CLRB
$19.8M
– –
-108
Closed -$395K
DVAX
275
DELISTED
Dynavax Technologies
DVAX
– –
-66,091
Closed -$318K
9 10
11
12 13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $725M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 18% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.